Oligonucleotides LC-MS: Support From Development To Release

Oligonucleotide therapeutics continue to expand rapidly, offering new treatment avenues through gene expression modulation, targeted protein reduction, and precision editing strategies. Yet their complex structures, chemical modifications, and charge characteristics require analytical approaches capable of delivering unambiguous identity, purity, and functional confirmation.

This piece highlights key LC‑MS–based strategies that bring clarity to these challenges — ranging from molecular‑weight and sequence confirmation to impurity profiling and nucleotide verification after enzymatic digestion. It also emphasizes the growing role of cell‑based potency assays paired with targeted MS readouts, enabling developers to quantify functional outcomes such as protein knockdown or restoration. Together, these techniques help ensure that increasingly sophisticated oligonucleotide modalities, from antisense and siRNA to aptamers and CRISPR guide RNAs, are thoroughly characterized from development through release.

Explore the full flyer to see how advanced LC‑MS workflows support confident decision‑making across every stage of the oligo lifecycle.